AIDS and HIV Information
Triumeq Generic: Find Out Everything about Triumeq Generic
According to United Nations AIDS agency (UNAIDS), there are around 37 million HIV-infected people worldwide, and only half of them are taking antiretroviral therapies (ART). The high cost of newly developed ART treatments, which are more potent and better tolerated, is a deterrent to the government’s initiatives of providing accessible treatment to low-income patients. Drug resistance is also a growing concern; development of new antiretroviral agents to combat resistance is necessary, but not without some drawbacks. New drugs are better yet expensive and their generic counterparts will not be available for the next 20 years or so.
Triumeq patent expiration
A generic version of Triumeq has not been approved in the United States. You many find online pharmacies selling illegal generic versions of this regimen. These drugs may be counterfeit and they have not been checked by the FDA; they may also contain potentially unsafe substances.
There may be several patents granted for each drug. One patent for Triumeq with the longest validity is set to expire in 2029. Exclusivity or exclusive marketing rights for ViiV Healthcare run until August 2018. The dates are only tentative as big pharmaceutical companies can extend marketing exclusivity in various ways, such as by applying for a new indication, co-formulating with another medicine with a longer patent life, or modifying the drug’s inactive components.
When will generic Triumeq be available?
Triumeq is composed of abacavir, lamivudine, and dolutegravir. It is currently included in the Department of Health and Human Services HIV guidelines as a recommended first-line treatment regimen for HIV-infected patients. It was granted FDA approval in 2014, so it probably won’t have a generic version this early—not even in the near future. However, some of the HIV medications included in Triumeq is already available in generic forms.
Teva, the world’s largest generic drug producer, has their own generic equivalent of Epzicom (abacavir + lamivudine) in 600mg/300mg tablet form. GlaxoSmithKline’s Epzicom is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. When used in combination with other HIV meds, it helps reduce the amount of virus and increase the number of immune cells (CD4+ T cells) in the patients’ blood to protect their bodies from infections.
How about dolutegravir (DTG)?
While the generic version of Tivicay (dolutegravir) is not yet available in the United States, a Tentative Approval was given to Aurobindo Pharma to supply the first generic version of dolutegravir 50mg in the developing world. The submission was supported by Tivicay makers, ViiV Healthcare, and Clinton Access Initiative (CHAI).
An Indian generic company was also given voluntary licenses by ViiV Healthcare and Medicines Patent Pool (MPP) to manufacture and market dolutegravir. Their generic version is now available in India since February 2017. Generic equivalent of the drug for adult and pediatric patients will also be sold royalty-free to 121 countries; thanks to an agreement signed by MPP and dolutegravir’s originator company. The availability of generic equivalents of recommended antiretroviral agents is crucial in extending treatments in poor countries and low-income patients in developed countries.
Low-cost generic antiretroviral regimens
The availability of generic dolutegravir means combination pills using the drug can also be developed without the high price point. Bill Gates’ charitable foundation, Mylan Laboratories, and Aurobindo Pharma signed an agreement to make a new dolutegravir-based combination pill available to 92 poor countries. The drug’s cost is set to a maximum of $75 per patient for a year’s supply. Africa will be the first region to benefit from this agreement. The new ART regimen is a fixed-dose combination of lamivudine, dolutegravir, and tenofovir disoproxil fumarate. Treatment regimens containing dolutegravir have demonstrated fewer side effects and excellent potency against drug resistance in Africa and other poor countries.
Patients who are looking for a generic form of Triumeq because of its high cost may need to look for another alternative. It is still not clear if a cheaper non-branded Triumeq will be available in the market, but you also have an option of taking multiple generic pills per day. The move to individual generic counterparts of abacavir, lamivudine, and dolutegravir may or may not benefit you. In the case of Triumeq, switching to branded dolutegravir (Trivicay) + generic abacavir and lamivudine could lower the cost of a monthly regimen from $2599 to $1932. But your savings is dependent on your health insurance programs, whether you are getting monetary aids from AIDS Drug Assistance Programs or private insurers.